Navigation Links
CK Life Sciences Announces U.S. FDA's Clearance to Commence Phase III Clinical Testing of Melanoma Vaccine
Date:3/6/2012

body's immune system to fight the cancer.

Preparation for the Phase III clinical trial is already underway, and it is expected that patient enrollment will commence within several months.

This latest development follows the approval Polynoma obtained from the FDA of a clinical trial protocol under a Special Protocol Assessment (SPA) agreement. An SPA is an agreement between the FDA and the applicant that a proposed protocol's design and analysis plan are acceptable to the FDA as support for potential future approval of a drug, biologic or vaccine, if the results of the clinical trial are positive. It is a process that can support the future registration and launching of the product.

Drug research and development requires extensive testing, involving multiple stages of compound screening as well as pre-clinical and clinical development (Phase I, II, III clinical trials) prior to approval and registration by health authorities such as the FDA. Phase III clinical testing is generally the last step before a drug can be submitted for approval for registration and sale, and involves the generation of controlled clinical trial results that are statistically significant and clinically relevant.

For enquiries, please call Mrs. Wendy Tong Barnes or Ms. Carolina Cheung of CK Life Sciences at +852-2122-2150.

About CK Life Sciences

CK Life Sciences Int'l., (Holdings) Inc. is a listed company on The Stock Exchange of Hong Kong Limited (stock code: 0775). Bearing the mission of improving the quality of life, the Company is engaged in the business of research and development, commercialisation, marketing and sale of health and agriculture related products. CK Life Sciences is a member of the Cheung Kong Group. For additional information, please visit www.ck-lifesciences.com.

About Polynoma LLC

Polynoma LLC is an oncology-focused biotechnology company based in
'/>"/>

SOURCE CK Life Sciences Int'l., (Holdings) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address rare diseases, ... Annual William Blair Growth Stock Conference to be held at ... , June 9-11, 2015. John Mendlein , ... presentation on the Company at 9:20 a.m. CT on Wednesday, ...
(Date:6/3/2015)... 3, 2015  GenVec, Inc. (NASDAQ: GNVC ) ... T. Curiel and his team from the School ... Louis (WUSTL).  Dr. Curiel is the director ... Division within the Department of Radiation Oncology. ... will create modified versions of GenVec,s gorilla adenovectors that ...
(Date:6/3/2015)... June 3, 2015  EIP Pharma LLC ( www.eippharma.com ... clinical development of VX-745 in Alzheimer,s disease (AD) is ... and potent inhibitor of the alpha isoform of the ... alpha). "Recent human genetic data demonstrate that ... with symptomatic Alzheimer,s, while the science also indicates the ...
Breaking Medicine Technology:GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 2GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 3GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 4EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... Telik, Inc. (Nasdaq: TELK ) today reported ...  The net loss for the quarter ended March 31, 2011 was $3.7 ... of $5.3 million, or $0.10 per share, for the same period ... in the first quarter of 2011 were $1.7 million, compared to ...
... WOONSOCKET, R.I., May 16, 2011 Obtaining prior authorization ... patients and pharmacists that currently requires phone calls, faxes ... available, they do not provide both a real-time solution ... electronic health record (EHR) tools.  Recognizing this gap in ...
Cached Medicine Technology:Telik Announces First Quarter 2011 Financial Results 2Telik Announces First Quarter 2011 Financial Results 3CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 2CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 3
(Date:6/3/2015)... 2015 DailyEndorphin is pleased to announce ... With this highly configurable new offering, DE's annual ... many components of its wellness programming for the entire ... , With this new module, annual clients may also ... Create participant surveys, (3) Continually report on participant progress ...
(Date:6/3/2015)... Foot and Ankle Specialists of the ... ( Clarksville Division ) was recently presented with the ... Wound Care (SAWC) and the American Podiatric Medical Association ... The Conference was held on April 29-May 3, 2015, ... Antonio, TX. , Dr. Casey Friske graduated from ...
(Date:6/3/2015)... evigilo, a world leader in delivering and developing ... by launching a new and enhanced content-centric website: ... logo depicting a sun-like image with a color movement ... Know. To Act. In time. The color palate, it ... borderless approach to alerting and delivering safety and sense ...
(Date:6/2/2015)... Concorde Career Colleges, Inc., announced today ... Bell will manage day-to-day operations for the privately held ... the opportunity to help our Concorde team deliver on ... Concorde in part due to reports like Beyond College ... in Memphis and Portland.” , Bell brings 14 years ...
(Date:6/2/2015)... On March 19th, 2015, LiveToBeSober.org held an ... of Legends at Detroit’s Ford Field. Hosted by former ... the goal of the conference was to raise awareness ... the benefits of effective professional rehabilitation programs. It also ... that are available to them in regards to the ...
Breaking Medicine News(10 mins):Health News:DailyEndorphin Launches Wellness "Events" Portal 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Receives Award at the Spring 2015 Symposium of Advanced Wound Care Conference 2Health News:Keep calm! evigilos' "sun" will come out tomorrow – to know, to act, in time. 2Health News:Concorde Career Colleges Announces New President and COO 2Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2
... A Boston University School of Medicine-led research team has ... Stem (iPS) cells, derived from mouse fibroblasts, by using ... the reprogramming process. The result is a powerful laboratory ... embryonic stem cell-like cells for clinical purposes such as ...
... the spinal column called the multifidus muscle may in fact ... to researchers at the University of California, San Diego School ... role of this poorly understood muscle has been published on ... Journal of Bone and Joint Surgery . , "The ...
... MORRIS PLAINS, N.J., Jan. 7 Immunomedics, Inc. ... focused on developing monoclonal antibodies to treat cancer and ... President and Chief Executive Officer, will be presenting at ... held in San Francisco, CA.Ms. Sullivan,s presentation, which is ...
... save on ice skating admission PHILADELPHIA, Jan. 7 ... families to attend this year,s Healthy Kids Fest on Sunday, ... Landing, from 1 p.m. to 5 p.m. Just in time ... fitness will feature music and free activities for the whole ...
... CKD Care and Your Practice Culture: Improve Your ... Association 2009 Annual Meeting, "CKD and Your ... in Baltimore, will include plenary sessions and interactive ... to today,s nephrology practitioners. RPA will convene ...
... Inc.,(NYSE: HI ) has appointed Jan ... on continuous improvement and operational excellence initiatives,across the ... team, reporting directly to President and CEO Kenneth ... recently serving as vice president of operations in ...
Cached Medicine News:Health News:Converting adult somatic cells to pluripotent stem cells using a single virus 2Health News:Unique skeletal muscle design contributes to spine stability 2Health News:Immunomedics to Present at 27th Annual J.P. Morgan Healthcare Conference 2Health News:Immunomedics to Present at 27th Annual J.P. Morgan Healthcare Conference 3Health News:Families Encouraged to Enjoy Healthy Kids Fest at the Blue Cross RiverRink January 11 2Health News:Renal Physicians Association 2009 Annual Meeting 2Health News:Hillenbrand, Inc. Appoints Jan Santerre Vice President of Lean Business 2
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000CVA test face is used to evaluate both ... levels (high, 25% and 12.5%) of LogMAR acuity ... face as well as the two spatial frequencies ... most widely used for cataract documentation because eye ...
... is used widely for screening refractive surgery ... from 20/10 to 20/100 and one row ... ,The patient can be easily screened in ... contrast sensitivity. If a contrast sensitivity deficit ...
Medicine Products: